IL214392A0 - Bicyclic amide derivatives for enhancing glutamatergic synaptic responses - Google Patents
Bicyclic amide derivatives for enhancing glutamatergic synaptic responsesInfo
- Publication number
- IL214392A0 IL214392A0 IL214392A IL21439211A IL214392A0 IL 214392 A0 IL214392 A0 IL 214392A0 IL 214392 A IL214392 A IL 214392A IL 21439211 A IL21439211 A IL 21439211A IL 214392 A0 IL214392 A0 IL 214392A0
- Authority
- IL
- Israel
- Prior art keywords
- amide derivatives
- bicyclic amide
- synaptic responses
- glutamatergic synaptic
- enhancing glutamatergic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Pulmonology (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US20664209P | 2009-02-02 | 2009-02-02 | |
PCT/US2010/000255 WO2010087981A2 (en) | 2009-02-02 | 2010-01-29 | Bicyclic amide derivatives for enhancing glutamatergic synaptic responses |
Publications (1)
Publication Number | Publication Date |
---|---|
IL214392A0 true IL214392A0 (en) | 2011-09-27 |
Family
ID=42396261
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL214392A IL214392A0 (en) | 2009-02-02 | 2011-08-01 | Bicyclic amide derivatives for enhancing glutamatergic synaptic responses |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP2391621A4 (en) |
JP (1) | JP2012516845A (en) |
KR (1) | KR20110115139A (en) |
CN (1) | CN102369201A (en) |
AU (1) | AU2010208646A1 (en) |
BR (1) | BRPI1005316A2 (en) |
CA (1) | CA2751285A1 (en) |
EA (1) | EA018994B1 (en) |
IL (1) | IL214392A0 (en) |
MX (1) | MX2011008060A (en) |
SG (1) | SG173168A1 (en) |
WO (2) | WO2010087981A2 (en) |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ255097A (en) * | 1992-07-24 | 2001-04-27 | Univ California | Heterocyclic derivatives (such as 1-(1,4-bgenzodioxan-5-ylcarbonyl)-1,2,3,6-tetrahydropyridine) and medicaments that enhance synaptic responses |
US20020099050A1 (en) * | 1993-07-23 | 2002-07-25 | Lynch Gary S. | Drugs that enhance synaptic responses mediated by AMPA receptors |
US6110935A (en) * | 1997-02-13 | 2000-08-29 | The Regents Of The University Of California | Benzofurazan compounds for enhancing glutamatergic synaptic responses |
CN1281335A (en) * | 1997-10-27 | 2001-01-24 | 科泰克斯药物股份有限公司 | Treatment of schizophrenia with ampakines and neuroleptics |
KR101599661B1 (en) * | 2007-05-17 | 2016-03-03 | 코텍스 파마슈티칼스, 인크. | Di-substituted amides for enhancing glutamatergic synaptic responses |
BRPI0823262A2 (en) * | 2007-08-10 | 2013-09-24 | Cortex Pharma Inc | Respiratory depression treatment method and use of a compound in the manufacture of a medicament for the treatment of respiratory depression |
-
2010
- 2010-01-29 CA CA2751285A patent/CA2751285A1/en not_active Abandoned
- 2010-01-29 AU AU2010208646A patent/AU2010208646A1/en not_active Abandoned
- 2010-01-29 MX MX2011008060A patent/MX2011008060A/en active IP Right Grant
- 2010-01-29 BR BRPI1005316A patent/BRPI1005316A2/en not_active IP Right Cessation
- 2010-01-29 CN CN2010800154033A patent/CN102369201A/en active Pending
- 2010-01-29 WO PCT/US2010/000255 patent/WO2010087981A2/en active Application Filing
- 2010-01-29 KR KR1020117019461A patent/KR20110115139A/en not_active Application Discontinuation
- 2010-01-29 SG SG2011054376A patent/SG173168A1/en unknown
- 2010-01-29 JP JP2011547981A patent/JP2012516845A/en active Pending
- 2010-01-29 EA EA201101162A patent/EA018994B1/en not_active IP Right Cessation
- 2010-01-29 WO PCT/US2010/000254 patent/WO2010087980A2/en active Application Filing
- 2010-01-29 EP EP10736150A patent/EP2391621A4/en not_active Withdrawn
-
2011
- 2011-08-01 IL IL214392A patent/IL214392A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
SG173168A1 (en) | 2011-08-29 |
CA2751285A1 (en) | 2010-08-05 |
EA018994B1 (en) | 2013-12-30 |
EP2391621A2 (en) | 2011-12-07 |
KR20110115139A (en) | 2011-10-20 |
JP2012516845A (en) | 2012-07-26 |
AU2010208646A1 (en) | 2011-09-01 |
BRPI1005316A2 (en) | 2019-09-24 |
EA201101162A1 (en) | 2012-01-30 |
EP2391621A4 (en) | 2012-07-25 |
MX2011008060A (en) | 2011-09-09 |
WO2010087981A3 (en) | 2011-03-24 |
WO2010087980A2 (en) | 2010-08-05 |
WO2010087980A3 (en) | 2011-02-24 |
WO2010087981A2 (en) | 2010-08-05 |
CN102369201A (en) | 2012-03-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1249580A1 (en) | Protein detection via nanoreporters | |
HK1147677A1 (en) | Bicyclic amides for enhancing glutamatergic synaptic responses | |
HK1177462A1 (en) | Triazolopyridine derivatives | |
IL232570B (en) | Bicyclic dihydroisoquinoline-1-one derivatives | |
BRPI1008749A2 (en) | Benzodiazepine Derivatives | |
PT2414322T (en) | Polyamine derivatives | |
IL202187A0 (en) | Di-substituted amides for enhancing glutamatergic synaptic responses | |
EP2456322A4 (en) | Amorphous protein extrudates | |
IL212285A0 (en) | Azaindole derivatives | |
GB201117171D0 (en) | Cuvette | |
IL211241A0 (en) | 7-azaindole derivatives | |
HK1171755A1 (en) | Spirocyclic amide derivatives | |
EP2497914A4 (en) | Camshaft apparatus | |
EP2490007A4 (en) | Cuvette | |
IL219603A0 (en) | Imidazopyridine derivatives | |
ZA201106792B (en) | Amide derivative | |
GB2467433B (en) | Combustion apparatus | |
EP2447264A4 (en) | N-substituted-cyclic amino derivative | |
ZA201200415B (en) | Amide derivative | |
IL213827A0 (en) | Benzothiazolone derivatives | |
AP2013006867A0 (en) | Indole derivatives | |
SG10201406505WA (en) | Methods for the detection of fatty-acylated proteins | |
IL214392A0 (en) | Bicyclic amide derivatives for enhancing glutamatergic synaptic responses | |
GB0918924D0 (en) | Azaindole derivatives | |
GB0912769D0 (en) | Combustion apparatus |